<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03702426</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-SBP-01</org_study_id>
    <nct_id>NCT03702426</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy of Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis</brief_title>
  <official_title>Comparison of the Efficacy of Granulocyte - Macrophage Colony Stimulating Factor (GM-CSF) and Norfloxacin in Secondary Prophylaxis for Spontaneous Bacterial Peritonitis - A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -Consecutive patients of decompensated cirrhosis of any etiology, presenting to the Institute
      of Liver and Biliary Sciences hospital with spontaneous bacterial peritonitis will be
      evaluated
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2018</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spontaneous Bacterial Peritonitis on secondary prophylaxis in both groups</measure>
    <time_frame>6 Month</time_frame>
    <description>Spontaneous Bacterial Peritonitis is defined as Polymorphonuclear count &gt; 250 in ascitic fluid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival in both groups after development of SBP (Spontaneous Bacterial Peritonitis ).</measure>
    <time_frame>4 weeks</time_frame>
    <description>Spontaneous Bacterial Peritonitis is defined as Polymorphonuclear count &gt; 250 in ascitic fluid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival in both groups after development of SBP (Spontaneous Bacterial Peritonitis ).</measure>
    <time_frame>12 weeks</time_frame>
    <description>Spontaneous Bacterial Peritonitis is defined as Polymorphonuclear count &gt; 250 in ascitic fluid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival in both groups after development of SBP (Spontaneous Bacterial Peritonitis ).</measure>
    <time_frame>24 weeks</time_frame>
    <description>Spontaneous Bacterial Peritonitis is defined as Polymorphonuclear count &gt; 250 in ascitic fluid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival in both groups after development of SBP (Spontaneous Bacterial Peritonitis ).</measure>
    <time_frame>48 weeks</time_frame>
    <description>Spontaneous Bacterial Peritonitis is defined as Polymorphonuclear count &gt; 250 in ascitic fluid.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <arm_group>
    <arm_group_label>Norfloxacin with GM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Norfloxacin 400mg daily and GM-CSF (Granulocyte-Macrophage colony-stimulating factor) in a dose of 1.5mcg/kg over 4 hour infusion every 15 days will be given in Group B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norfloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who fulfil the inclusion criteria will receive oral norfloxacin 400 mg daily as secondary prophylaxis for SBP in Group A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GMCSF</intervention_name>
    <description>GMCSF 1.5mcg/Kg</description>
    <arm_group_label>Norfloxacin with GM-CSF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norfloxacin</intervention_name>
    <description>Tablet Norfloxacin 400 mg</description>
    <arm_group_label>Norfloxacin</arm_group_label>
    <arm_group_label>Norfloxacin with GM-CSF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 - 70years

          -  Patients of decompensated liver cirrhosis who present with spontaneous bacterial
             peritonitis (Presence of more than 250 neutrophils per cc of ascitic fluid, in the
             absence of a surgical abdomen, in the presence of decompensated cirrhosis and portal
             hypertension) that has responded to standard medical care.

        Exclusion Criteria:

          -  Allergic to quinolones

          -  Advanced HCC (Hepatocellular Carcinoma)

          -  Post liver transplant

          -  HIV (Human Immunodeficiency Virus) positive patients

          -  Patients on immunosuppressive therapy

          -  Pregnancy

          -  Acute Liver Failure

          -  History of hematological malignancy or bone marrow transplantation

          -  No informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norfloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

